Preprint Review Version 1 This version is not peer-reviewed

Genome Editing for the Understanding and Treatment of Cardiomyopathies

Version 1 : Received: 28 December 2019 / Approved: 29 December 2019 / Online: 29 December 2019 (13:41:48 CET)

A peer-reviewed article of this Preprint also exists.

Nguyen, Q.; Lim, K.R.Q.; Yokota, T. Genome Editing for the Understanding and Treatment of Inherited Cardiomyopathies. Int. J. Mol. Sci. 2020, 21, 733. Nguyen, Q.; Lim, K.R.Q.; Yokota, T. Genome Editing for the Understanding and Treatment of Inherited Cardiomyopathies. Int. J. Mol. Sci. 2020, 21, 733.

Journal reference: Int. J. Mol. Sci. 2020, 21, 733
DOI: 10.3390/ijms21030733

Abstract

Cardiomyopathies are diseases of heart muscle, a significant percentage of which are genetic in origin. Cardiomyopathies can be classified as dilated, hypertrophic, restrictive, arrhythmogenic right ventricular or left ventricular non-compaction, although mixed morphologies are possible. A subset of neuromuscular disorders, notably Duchenne and Becker muscular dystrophies, are also characterized by cardiomyopathy aside from skeletal myopathy. The global burden of cardiomyopathies is certainly high, necessitating further research and novel therapies. Genome editing tools, which include zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) and clustered regularly interspaced short palindromic repeats (CRISPR) systems have emerged as increasingly important technologies in studying this group of cardiovascular disorders. In this review, we discuss the applications of genome editing in the understanding and treatment of cardiomyopathy. We also describe recent advances in genome editing that may help improve these applications, and some future prospects for genome editing in cardiomyopathy treatment.

Subject Areas

dilated cardiomyopathy (DCM); hypertrophic cardiomyopathy (HCM); restrictive cardiomyopathy (RCM); arrhythmogenic right ventricular cardiomyopathy (ARVC); left ventricular non-compaction cardiomyopathy (LVNC); Duchenne muscular dystrophy; dystrophin; genome editing; CRISPR/Cas9; Cpf1 (Cas12a)

Comments (1)

Comment 1
Received: 10 January 2020
Commenter: Ian M MacDonald
The commenter has declared there is no conflict of interests.
Comment: This article provides useful insights into current thinking about gene therapies in the cardiomyopathies and heritable disorders.
+ Respond to this comment

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 1
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.